Almirall and Sun Pharma announce regulatory filing of tildrakizumab in Europe
Pivotal Phase 3 data demonstrated potential of Tildrakizumab to offer patients treatment for moderate-to-severe plaque psoriasis…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.